Veeva Systems Inc Class A

Veeva Systems announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS directly from a study protocol, enabling clinical studies to be configured in as little as one day. The agent reuses an organization's existing standards and leverages the CDISC Unified Study Definitions Model, or USDM, to deliver faster and more deterministic study builds. It configures EDC forms, visits, and edit check rules, as well as CQL-based listings in DQS, and automates testing, including the generation of test data. Drew Garty, chief technology officer of Veeva Clinical Data, said the agent will make it much faster to build high-quality studies. Planned for early adopter availability in December 2026, Veeva Study Builder Agent is part of EDC and requires no additional license, and it is delivered as a Claude Cowork plugin installed from a Veeva-managed GitHub repository.

Veeva Systems announced a new top 20 biopharma commitment for its Vault CRM, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is positioned as the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness. The company said Vault CRM serves as a foundation for agentic commercial, helping transform how the industry engages healthcare professionals, with innovations such as the Agentic Call Report generating Commercial Evidence. Arno Sosna, president of CRM Suite at Veeva, said the company is working with customers as Vault CRM drives the shift to agentic commercial, establishing a new way of working that helps bring medicines to patients faster and more efficiently. Vault CRM is part of the Veeva Vault CRM Suite, which connects sales, marketing, and medical for more effective, customer-centric, and compliant engagement across channels.

Amgen has selected Veeva Systems' Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it advances new therapies across worldwide markets, with Amgen saying the migration will help accelerate delivery of new therapies with greater speed and agility. The win reinforces Veeva's commercial business, where management recently described fiscal second-quarter 2027 as its best CRM quarter ever, with commercial subscription revenue growing about 13% year over year. Vault CRM now has more than 180 live customers, and management reiterated confidence in maintaining more than 70% market share in life sciences CRM. Veeva currently has a market capitalization of $42.13 billion, and its shares have gained 16.8% year to date.

Veeva Systems announced that Regeneron and Biogen have adopted its AI-powered Vault CRM suite globally, and introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. These moves expand Veeva's AI-focused offerings across commercial and safety workflows in life sciences, reinforcing its position as a key provider of industry-specific cloud software. With a market cap of about $45.5 billion, Veeva is a large specialist in healthcare software, and these global commitments signal deeper integration of its AI tools into core biopharma operations, potentially increasing switching costs and making multi-year relationships more durable. The company plans a November 2026 rollout for Falcon Safety, and investors will watch for early adopters and quantified updates in upcoming earnings calls to gauge traction.

Veeva Systems raised its fiscal 2027 outlook after second-quarter revenues increased 17.6% year over year to $928 million, driven by Vault CRM adoption and broader commercial execution. The company now expects fiscal 2027 revenues of $3.682-$3.687 billion, subscription revenues of about $3.08 billion, and adjusted earnings of roughly $9.21 per share, implying about 15% growth at the high end. Management also projects approximately $1.64 billion in non-GAAP operating income, with a roughly 44% non-GAAP operating margin. Vault CRM recorded its best quarter to date, with two additional top-20 biopharma selections, bringing commitments to 12 of the top 20, and more than 180 customers are live on the platform. Falcon, Veeva's agentic AI product, has five early adopters including a top-20 pharma company, with first go-lives expected in 2026, though monetization remains early. R&D and Quality subscription revenues rose 19% year over year to $419.4 million in the second quarter, as newer products like EDC, eCOA, RTSM, Safety, and LIMS are expected to become more important. Veeva currently carries a Zacks Rank #3 (Hold), with a Value Score of D, a Growth Score of B, a Momentum Score of A, and a VGM Score of B.

Moderna led the S&P 500 in August after reporting promising results from a late-stage trial of a personalized mRNA cancer vaccine co-developed with Merck, according to CNBC. The data challenged years of skepticism about the company's mRNA technology following the decline of its Covid-19 vaccine business. Enterprise software stocks accounted for many of the index's other top performers, including Palantir, Veeva Systems, Salesforce, and ServiceNow, which had been under selling pressure due to AI concerns and large short positions held by the leveraged hedge fund Situational Awareness. When the fund was forced to unwind its trades in late July, those shorts became a tailwind for the stocks. Situational Awareness, run by Leopold Aschenbrenner, peaked at $45 billion in assets and lost roughly $35 billion after margin calls from prime brokers Bank of America, Goldman Sachs, and JPMorgan Chase forced a distressed sale to Ken Griffin's Citadel. Salesforce bounced back after better-than-expected quarterly results, while ServiceNow gained on AI integration, and Veeva Systems climbed as the anticipated AI threat failed to materialize. Outside software, Newmont benefited from gold price recovery, Coinbase rose with cryptocurrencies, and Super Micro Computer and Sandisk surged on AI memory demand. Moderna also raised $2 billion through convertible senior notes due 2032, earmarked for its cancer vaccine business, after its stock surged 177% on Aug. 19, adding $44.5 billion to its market capitalization in a single session.

Veeva Systems announced Veeva Falcon Safety, an agentic safety operations product designed to streamline adverse event intake, case processing, and follow-up for biopharma companies. Falcon Safety will work with any E2B-compliant safety system, including Oracle Argus and ArisGlobal LifeSphere MultiVigilance, in addition to Veeva Safety. The product is planned for early adopter availability in November 2026 and is part of Veeva AI, the company's industry-specific AI solutions for life sciences. Marius Mortensen, vice president of product for Falcon at Veeva, said the product builds on Veeva's partnership with case processors and pharmacovigilance experts to help reinvent safety operations.

Veeva Systems reported fiscal second-quarter revenue of $928 million, up 18% year over year, with subscription revenue rising 16% to $766.8 million and GAAP operating income climbing 40% to $275 million, lifting the operating margin to 29.6% from 24.8%. However, the prior-year quarter included a $30.6 million litigation settlement charge, and excluding that item would put the earlier margin near 28.7%, making the underlying expansion closer to one percentage point. Subscription growth remains strong, with more than 180 customers live on Vault CRM and 12 of the top 20 biopharmaceutical companies committed to the platform, while the company added over 30 clinical customers and surpassed 100 Veeva Safety customers. Non-GAAP operating income rose 18% to $415.9 million, with the margin edging up to 44.8% from 44.7%, but operating cash flow was nearly flat at $238.7 million and professional-services gross margin declined to 31.5% from 33.4%. For fiscal 2027, Veeva expects revenue of $3.682 billion to $3.687 billion and non-GAAP operating income of about $1.64 billion, implying a margin of approximately 44.5%, which management characterized as about 44%, suggesting continued high profitability but not obvious expansion from fiscal 2026's 44.9%.

Nvidia surged 9% after second-quarter revenue and earnings beat expectations, with adjusted earnings of $2.22 per share on $96.22 billion in revenue, surpassing analyst estimates of $2.10 per share and $92.17 billion, and the company forecast third-quarter revenue of $108 billion. Salesforce soared 21% after adjusted earnings of $5.90 per share beat an LSEG estimate of $3.27, while Okta jumped over 27% on better-than-expected results and raised guidance. Veeva Systems climbed 16% on strong quarterly results and upbeat guidance, but HP fell 4% despite beating revenue estimates due to concerns over memory costs and margins. Moderna dropped 4% after proposing a $2 billion convertible notes sale, Celsius fell nearly 6% on a Deutsche Bank downgrade, and Wendy's tumbled 13% after reports that Trian Fund Management won't pursue a buyout. Dollar General rose 5% after raising full-year guidance, while Dollar Tree, Burlington Stores, Best Buy, and Hormel Foods declined on various earnings-related concerns.

Veeva Systems reported quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.22 per share, and compared to $1.99 per share a year ago. Revenue for the quarter ended July 2026 was $927.96 million, surpassing the consensus estimate by 2.64% and up from $789.08 million in the prior year. The company has exceeded EPS and revenue estimates in each of the last four quarters. Veeva shares have gained about 10.6% since the start of the year, underperforming the S&P 500's 12.2% gain. The current consensus EPS estimate for the coming quarter is $2.28 on $918.02 million in revenues, and for the fiscal year it is $9.05 on $3.64 billion in revenues.

Veeva Systems announced that Biogen has committed to Veeva Vault CRM globally. The unified commercial platform is intended to help speed the delivery of medicines to patients. Tom Schwenger, president and CCO at Veeva, said Vault CRM will serve as the agentic commercial foundation for Biogen as it delivers medicines that transform patients' lives. Guy Hadari, senior vice president and global CIO at Biogen, said the companies share a deep commitment to customer experience and innovation, and Biogen is excited to expand its strategic partnership with Veeva by moving to Vault CRM. Vault CRM is part of the Vault CRM Suite, which includes the Agentic Call Report to generate Commercial Evidence.

The analyst-derived fair value estimate for Veeva Systems has risen from $245.48 to $251.43 per share. The revision reflects updated assumptions including revenue growth moving from 12.43% to 12.68%, net profit margin adjusting from 30.23% to 29.94%, and future P/E multiple increasing from 34.48x to 35.24x. Bullish analysts from firms such as Guggenheim, Stifel, and Piper Sandler cite solid Q1 results, CRM share gains, and early AI adoption, while bearish voices from Goldman Sachs, UBS, and Citi flag AI disruption risk and CRM competition. The fair value shift signals a modest reset in how the stock is being valued amid mixed Wall Street commentary.

Veeva Systems has secured Eli Lilly and Company's commitment to deploy Veeva Vault CRM globally, while announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. The Eli Lilly win reinforces the thesis that top 20 pharma are increasingly willing to consolidate critical commercial workflows on Veeva's platform, tying directly into consensus expectations for continued subscription and services growth. Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, with the company's narrative projecting $4.7 billion revenue and $1.4 billion earnings by 2029, requiring 12.7% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today. Some analysts expect Veeva to reach about US$4.5 billion in revenue and US$1.3 billion in earnings by 2029, while the most cautious voices see AI agents, especially in Safety and clinical workflows, as a swing factor that could reshape those forecasts. The leadership change in Sales and Services does not appear to materially shift the biggest short term risk around customer concentration and contract renewals.

Eli Lilly and Company has committed to deploying Veeva Systems' Vault CRM globally, Veeva announced on August 11. Vault CRM serves as the core infrastructure for Veeva's AI-driven commercial framework, designed to modernize field engagement and speed medicine delivery. The partnership highlights how technology and drug development are becoming deeply intertwined, with Veeva as the tech engine and Eli Lilly as the pharmaceutical titan. In its fiscal 2027 first quarter, Veeva reported total revenue of $882.9 million, up 16% year-over-year, while Eli Lilly's second quarter 2026 revenue surged 48% to $22.97 billion, driven by GLP-1 therapies Mounjaro and Zepbound. Eli Lilly also raised its full-year 2026 revenue guidance to $85.0–$87.0 billion.

The global eClinical solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a compound annual growth rate of 13.98 percent, according to a report by Healthcare Foresights. The market was valued at approximately USD 11.50 billion in 2025 and is expected to reach USD 13 billion in 2026. Key players include Oracle, IQVIA, Veeva Systems, and Medidata Solution Inc. North America currently dominates the market, while the Asia-Pacific region is expected to see the highest growth rate. The report segments the market by product, delivery mode, development phase, and region.

Fundsmith Equity Fund highlighted Veeva Systems as a picks-and-shovels investment in drug development in its second-quarter 2026 investor letter. The fund noted that Veeva provides specialized cloud-based software for the pharmaceutical and life sciences industries, tracking the entire drug lifecycle from clinical trials through manufacturing and sales. Veeva holds roughly 80% market share in pharmaceutical customer relationship software, and its competitive moat is built on extremely high switching costs, as replacing the software risks halting clinical trials or drug manufacturing. Growth is fueled by upselling new modules to existing clients and using AI agents to manage administrative work in drug trials. The fund reported that Veeva's return on invested capital, excluding a large cash balance, is well in excess of 100%, with a free cash flow yield of 5.7%.

Veeva Systems raised its fiscal 2027 revenue guidance to about $3.65 billion and adjusted EPS outlook to roughly $9.05, following fiscal Q1 2027 results that exceeded its own guidance and showed stronger profitability helped by expanding AI-driven offerings. The upgrade was supported by the preview of Vault AI Agents and the Falcon agentic labor platform, which are designed to automate work in clinical operations, safety case handling, and quality documentation. The company's investment narrative now projects $4.7 billion in revenue and $1.4 billion in earnings by 2029, requiring 12.4% yearly revenue growth and an earnings increase of about $0.5 billion from $941.7 million today. Before the guidance hike, the most optimistic analysts were already modeling about $5.0 billion of revenue and $1.6 billion of earnings by 2029, leaning heavily on faster AI agent adoption. How quickly customers adopt these AI capabilities will likely influence whether the upgraded outlook proves conservative or ambitious.

Veeva Systems shares have gained about 7.9% since its last earnings report, outperforming the S&P 500. The company reported adjusted earnings per share of $2.24 for the first quarter of fiscal 2027, up 13.7% year over year and beating the Zacks Consensus Estimate by 5.2%. Total revenues reached $882.9 million, a 16.3% increase, driven by subscription services revenue of $730.2 million and professional services revenue of $152.8 million. For the fiscal second quarter, Veeva expects total revenues between $902 million and $905 million, with adjusted earnings per share of $2.21 to $2.22. Full-year fiscal 2027 revenue guidance was raised to between $3,635 million and $3,645 million, and adjusted earnings per share is expected to be approximately $9.05.

Stifel has reiterated its Buy rating and $230 price target on Veeva Systems following the company's acquisition of Copli. Veeva announced on June 23 the acquisition of the agentic medical, legal, and regulatory solutions firm, rebranding it as Veeva Falcon MLR, which aims to accelerate content review and potentially eliminate 70% or more of manual MLR labor within five years. The company also launched Veeva EHS on June 25, a new environmental, health, and safety application within Veeva Quality Cloud, enabling manufacturing and testing sites to manage operational and environmental risk and ensure global compliance readiness.

Shares of Guidewire Software, Veeva Systems, and Paycom surged in afternoon trading after Guggenheim analyst John DiFucci upgraded Salesforce and ServiceNow to Buy on valuation grounds, arguing that AI-disruption fears had pushed the sector too low. DiFucci, a previously cautious analyst, wrote that he was not upgrading because he sees ServiceNow as an AI beneficiary, calling near-term AI monetization unlikely and AI risks very real, but that the darkest scenario was already priced in. The read-through lifted the group, with Guidewire Software jumping 6.5%, Veeva Systems gaining 5.1%, and Paycom rising 6.2%. Oracle also added about 2% after being added to William Blair's July Analyst Conviction List and on news of a new AI product.

Veeva Systems shares rose more than 11.5% in the past week following the acquisition of Copli and the launch of the AI-driven Veeva Falcon MLR platform. On June 23, Veeva acquired Copli, a provider of agentic medical, legal, and regulatory solutions for life sciences, and made it available as Veeva Falcon MLR, aiming to reduce manual MLR labor by 70% or more within five years. On June 25, the company announced Veeva EHS, a new environmental, health, and safety application within Veeva Quality Cloud, with early adopter availability planned for August 2026. Of 29 analysts covering the stock, 20 rate it Buy and 8 rate it Hold, with an average price target of $235 implying over 37% upside. Year to date, however, the shares are down more than 23%.

Veeva Systems has acquired Copli, a pioneer in agentic medical, legal and regulatory solutions for life sciences, and simultaneously launched Veeva Falcon MLR, an AI-powered solution designed to accelerate content review and approval processes. Falcon MLR automates compliance checks against approved product labels and country-specific regulations, with the potential to eliminate more than 70% of manual MLR labor over the next five years. The solution is built on Copli's technology and integrates with Veeva PromoMats, strengthening the company's Commercial Cloud business. The acquisition expands Veeva's AI portfolio and is expected to drive customer adoption, deepen platform stickiness, and create cross-selling opportunities. Veeva currently has a market capitalization of $27.84 billion.

Veeva Systems has acquired Copli and launched Veeva Falcon MLR, an agentic medical, legal, and regulatory content-review platform now available immediately. The platform automates reviews of promotional and medical content by checking materials against approved labels and local regulations, with the potential to eliminate more than 70% of manual MLR work over the next five years. Copli CEO Jacob Scheel-Bech called the launch a fundamental shift in content review, noting the acquisition will help scale the company's vision for AI-focused MLR while merging its technology with Veeva PromoMats. Emma Hyland, vice president of Veeva Commercial Content, said the MLR process has long slowed the delivery of information to patients and physicians, and that Veeva Falcon MLR can shorten review cycles by automating routine work, allowing reviewers to focus on higher-value responsibilities.

Veeva Systems has launched Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud, designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness. The solution enables real-time safety incident reporting, end-to-end investigation management, and automated compliance workflows, integrating with Veeva QMS and Veeva Training to automatically create quality deviations and assign relevant training. Veeva EHS is expected to be available to early adopters in August 2026. The environmental health and safety software market is valued at 8.9 billion dollars in 2026 and is projected to grow at a compound annual growth rate of 8.1 percent through 2030, driven by stringent regulatory requirements, digital transformation, and the integration of artificial intelligence and machine learning.

Brown Capital Management’s Small Company Fund argues that Veeva Systems is relatively well insulated from AI-driven disruption because its cloud-based software is deeply embedded in specialized regulatory, clinical, and commercial workflows for the life sciences industry. The fund notes that Veeva’s platform relies on proprietary, highly structured data tied to drug development and compliance, making it less susceptible to commoditization by AI trained on public data. It also highlights that Veeva operates as a system of record for regulated content, unlike more easily disrupted interface-driven systems of engagement. Despite these defensive qualities, the stock is trading at a 55% discount to its historical price-to-sales ratio, which the fund attributes largely to an AI-related derating. Veeva Systems closed at $159.71 per share on June 23, 2026, with a market capitalization of $25.94 billion, and its shares have lost 42.86% over the past 52 weeks.

The global pharmacovigilance automation market is projected to grow from USD 2.80 billion in 2025 to USD 5.25 billion by 2035, at a compound annual growth rate of 6.50 percent. Software held a 72.40 percent share of the market in 2025, while the services segment is the fastest growing at a CAGR of 8.77 percent. Cloud-based deployment accounted for 49.80 percent of the market in 2025, and the SaaS segment is expected to record the highest CAGR of 13.02 percent. Artificial intelligence dominated with a 41.30 percent share in 2025, and natural language processing is the fastest growing technology segment at a CAGR of 13.73 percent. Pharmaceutical companies led end users with a 58.60 percent share in 2025, while biotechnology companies are the fastest growing at a CAGR of 11.57 percent. North America held a 38.60 percent share of the global market in 2025, and the Asia-Pacific region is the fastest growing regional market with a CAGR of about 8.92 percent.

Veeva Systems reported strong first-quarter results for fiscal 2027, with total revenues climbing 16% year-over-year to $882.9 million and subscription revenues rising 15% to $730.2 million, exceeding its own guidance across all metrics and prompting an increase in its full-year financial outlook. The company is advancing a strategic shift toward becoming an AI agent company, integrating conversational AI through its acquisition of Ostro, expanding Vault AI, and planning an early adopter release of Veeva Falcon in November, a platform designed to deliver agentic labor for clinical, regulatory, and safety workflows. Its commercial momentum continued with 27 new Vault CRM customers added in the quarter, pushing total live implementations past 150.

Nvidia CEO Jensen Huang stated at a recent technology trade show that it is a great time to be a software company, arguing that artificial intelligence will improve their products and services rather than replace them. Veeva Systems, a SaaS leader for the life sciences sector, reported fiscal first-quarter revenue of $882.9 million, up 16% year over year, and launched Veeva AI, an agentic AI system. Adobe posted record second-quarter revenue of $6.62 billion, a 13% increase, with AI-first annualized recurring revenue surpassing $500 million, a threefold year-over-year jump. Both stocks have declined recently but maintain strong competitive advantages and are incorporating AI into their offerings.